Cadrenal Therapeutics, Inc. (CVKD) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.10

From 52W high−91.65%

Volume31766.00

Market cap$3.80M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.10

From 52W high

−91.65%

Volume

31766.00

Market cap

$3.80M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

53.7

MomentumView details →

1D Return

−5.75%

YTD Return

−83.92%

SummaryUpdated Jun 1, 2026

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company founded in 2022 and headquartered in Ponte Vedra, Florida. The company went public in January 2023 and focuses exclusively on developing a single therapeutic candidate called Tecarfarin, designed to address a critical unmet medical need in patients with end-stage kidney disease who also suffer from atrial fibrillation.

Ask drillr about Cadrenal Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−282.13%

ROA (TTM)

−206.55%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+44.88%

FCF YoY

+12.95%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+23.94%

EBITDA YoY

+18.02%

MomentumView details →

1D Return

−5.75%

YTD Return

−83.92%

1Y Return

−91.45%

RSI (14)

53.7

vs 50D SMA

−1.99%

vs 200D SMA

−71.64%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.73x

Quick Ratio

3.73x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.14

EPS Surprise

19.72%

Beats (12Q)

3/12

Next Q EPS Est

−$0.86

Avg Surprise (4Q)

0.72%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−11.54M

Op. CF (TTM)

−10.16M

Next earningsNov 9, 2026 →

Latest newsMore news →

Cadrenal Therapeutics, Inc. initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.28d ago

Cadrenal Therapeutics, Inc. appointed Quang X. Pham as a Class I director effective September 24, 2026.36d ago

Similar companies

Liminatus Pharma, Inc. Class A Common StockLIMN PharmaCyte Biotech, Inc.PMCB OSR Holdings, Inc.OSRH Dermata Therapeutics, Inc.DRMA XTL Biopharmaceuticals Ltd.XTLB Medicus Pharma Ltd. Common StockMDCX Find similar companies →

Latest newsMore news →

Cadrenal Therapeutics, Inc. initiated a formal strategic process to evaluate opportunities to maximize the value of the company and its asset portfolio.28d ago Cadrenal Therapeutics, Inc. appointed Quang X. Pham as a Class I director effective September 24, 2026.36d ago